IMVT
Immunovant·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
Significant Net Income Decline
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About IMVT
Immunovant, Inc.
A clinical-stage biopharmaceutical company that developing therapies for autoimmune diseases
320 West 37th Street, New York, NY 10018
--
Immunovant, Inc., incorporated in Delaware on December 6, 2018, is a clinical-stage biopharmaceutical company focused on providing a normal life for patients with autoimmune diseases.
Earnings Call
Q2/2026
Estimate EPS-0.73
Actual EPS-0.73
Estimate Revenue--
Actual Revenue0
Immunovant's Q2 2026 Earnings Call: Contradictions Emerge on Graves' Disease Strategy, ACPA's Role in RA, FcRn Prioritization, and TED Patient Focus
Nov 10,2025 04:27
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
IMVT has released its 2026 Q2 earnings. EPS was reported at -0.73, versus the expected -0.73, meeting expectations. The chart below visualizes how IMVT has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
